8-K - BioNexus Gene Lab Corp. | StockGist

Current Report Details

Event Type

Material Agreement

Securities Issuance

Regulation

Disclosure

Mandatory

Variant

8-K

Items Reported

1.01

. Entry into a Material Definitive Agreement. On November 28, 2025, the Company entered into two (2) material definitive agreements described herein below. A. A

Material Agreement

$500.0M$4.32

Source Document

3.02

Unregistered Sales of Equity Securities. As described under Item 1.01 of this Current Report on Form 8-K, on November 28, 2025, the Company issued (i) 175,000 s

Securities Issuance

7.01

and Exhibits 99.1 and 99.2 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Item 9.01. Financial State

Regulation Fd

Exhibits (5)

10.1

EQUITY PURCHASE AGREEMENT

10.2

EXCLUSIVE INTELLECTUAL PROPERTY LICENSE AGREEMENT

8-K

FORM 8-K

99.1

PRESS RELEASE

99.2

PRESS RELEASE